Baxter International (BAX) : Traders are bullish on Baxter International (BAX) as it has outperformed the S&P 500 by a wide margin of 0.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.3%, relative to the S&P 500. The stock has risen by 4.86% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.4% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 1.44% and the 50-Day Moving Average is 0.44%.The 200 Day SMA reached 12.46% Baxter International Inc. is up 6.69% in the last 3-month period. Year-to-Date the stock performance stands at 25.01%.
Baxter International (BAX) : 8 Wall Street analysts covering Baxter International (BAX) believe that the average level the stock could reach for the short term is $50.75. The maximum price target given is $60 and the minimum target for short term is around $47, hence the standard deviation is calculated at $4.23.
Company shares have received an average consensus rating of Hold for the current week Baxter International (NYSE:BAX): The stock opened at $47.09 and touched an intraday high of $47.4 on Friday. During the day, the stock corrected to an intraday low of $46.75, however, the bulls stepped in and pushed the price higher to close in the green at $47.28 with a gain of 0.45% for the day. The total traded volume for the day was 14,556,977. The stock had closed at $47.07 in the previous trading session.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.